Streetbeat News

Products Services

ISPC

iSpecimen has launched a new virtual cancer sequencing procurement program. The program provides researchers with direct access to mutation-characterized formalin-fixed, paraffin-embedded cancer tumor tissues, addressing a significant bottleneck in cancer research. Initially, the program will offer samples for lung, colon, and breast cancers.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 11:39 am

EXAS

Exact Sciences Corp. (NASDAQ:EXAS) has been selected by the National Cancer Institute (NCI) to participate in the ComboMATCH clinical trials. The company's testing laboratory in Phoenix, AZ will use its new OncoExTra test to analyze tumor tissue and blood samples from patients, providing a comprehensive molecular picture of the patient's cancer and actionable results.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 11:33 am

ABEO

Abeona Therapeutics Inc. (NASDAQ:ABEO) has announced its intention to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EB-101, its investigational autologous, engineered cell therapy, for patients with recessive dystrophic epidermolysis bullosa (RDEB). This follows a successful pre-BLA meeting with the FDA.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 11:33 am

IFRX

InflaRx's Marketing Authorization Application (MAA) for Vilobelimab, a treatment for critically ill COVID-19 patients, is currently under review by the European Medicines Agency (EMA).

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 11:32 am

ALZN

Alzamend Neuro Inc (NASDAQ:ALZN) has submitted an investigational new drug (IND) application to the FDA for a Phase 2A study of AL001 for bipolar disorder. AL001 is a novel lithium-delivery system that can potentially deliver the benefits of marketed lithium salts while mitigating or avoiding currently experienced toxicities associated with lithium. The company aims to replace a 300 mg TID lithium carbonate dose for bipolar disorder with a 240 mg TID AL001 lithium equivalent, representing a daily decrease of 20% of lithium given to a patient.

Portfolio Pulse from Vandana Singh

August 30, 2023 | 11:31 am

ALZN

Alzamend Neuro has indicated that the safety aspects of its AL001 development may qualify for the (505)(b)(2) pathway for FDA approval. This could potentially expedite the approval process for the drug.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 11:30 am

ALZN

Alzamend Neuro has submitted an Investigational New Drug (IND) application to the US FDA for a Phase IIA clinical trial of AL001 in bipolar disorder patients.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 11:30 am

RGNX

Regenxbio has presented initial interim data from a first-in-human trial of RGX-181 for late-infantile neuronal ceroid lipofuscinosis type 2 disease, a form of Batten disease, at the Society for the Study of Inborn Errors of Metabolism.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 11:14 am

IE

Ivanhoe Electric's 90%-owned subsidiary, VRB Energy, has achieved global safety certification for its third-generation vanadium redox flow batteries. This certification could potentially increase the company's market share and competitiveness.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 11:14 am

ZFOX

ZeroFox, a cybersecurity company, has enhanced its physical security intelligence with powerful interactive mapping capabilities and comprehensive threat research. The company's new features aim to provide a more detailed and interactive view of physical security threats.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 11:13 am